Posts filtered by tags: Astrazeneca[x]


 

AstraZeneca Up This Year on New Drugs & Pipeline Progress

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Tags: Science, Astrazeneca


Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker.In the early 2000s, before the FDA approved Celgene’s flagship multiple myeloma drug lenalidomide (Revlimid), Novartis (NYSE: NVS considered buying the company. It passed, unwilling to risk billions on an unapproved drug. Those details came from biopharma dealmaker George...
Tags: Deals, Startups, China, Ipo, Cancer, Trends, Investing, Merck, Colorectal Cancer, Multiple Sclerosis, Harvard University, Health Insurance, Astrazeneca, Center For Medicare And Medicaid Services, Fda, National


4 attractive income shares? AstraZeneca plc, SSE PLC, Tesco PLC and Barratt Developments Plc - Investomania

   Investomania Could these stocks deliver improving dividend outlooks? AstraZeneca plc (LON:AZN) (AZN.L), SSE PLC (LON:SSE) (SSE.L), Tesco PLC (LON:TSCO) (TSCO.
Tags: Shopping, Astrazeneca, Tesco PLC, Barratt Developments Plc Investomania, SSE PLC Tesco PLC


Bio Roundup: Pharma in DC, Bristol-Cel in Trouble, Roche Gets A Spark

Could a shareholder revolt doom the planned marriage of Bristol-Myers Squibb and Celgene? Analysts have hinted at the possibility since the two companies shook hands in January, but the threat became real this week.Bristol (NYSE: BMY) and Celgene (NASDAQ: CELG) have campaignned heavily, starting with a joint presentation by their CEOs at the J.P. Morgan Healthcare Conference in January. Celgene drugs that should come to market the next two years will unlock $15 billion in annual revenue. The co...
Tags: Deals, Startups, Ge, Trends, Merck, Vc, Astrazeneca, Fda, National, Bristol, Novartis, Pfizer, Life Sciences, Clinical Trials, Celgene, Amgen


Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans

Swallowing a pill is a convenience that’s not available for all drugs. The cells and proteins in biological therapies can’t survive digestive enzymes, whose role is to break things down. That’s why insulin and other biologics must be injected.But what if there were a pill you could swallow that administers the injection inside your body? That’s the idea behind Rani Therapeutics, a medical technology company that has developed a “robotic pill” and is financially backed by some of world’s biggest...
Tags: Google, Startups, Drugs, San Francisco, Trends, Astrazeneca, Fda, Novartis, Shire, Biotech, Insulin, Medical Device, Alphabet, Life Sciences, Drug Delivery, Clinical Trials


Pharma companies want the government to do something about high drug prices, so long as it's not forcing them to lower their drug prices

Pharmaceutical CEOs and executives from seven companies went in front of Congress on Tuesday   to testify about the high price of prescription drugs. Over the course of a few hours, senators grilled the executives about the role they play in setting high prices for Americans as well as what they could do to fix it.  Toward the end, the executives seemed to reach a consensus that it'll take government action to solve the conundrum of how we get to lower prices.  One government action they don't...
Tags: Congress, Oregon, US, America, Trends, Merck, Iowa, Chuck Grassley, Astrazeneca, Medicare, Pascal Soriot, Wyden, Kenneth Frazier, Ron Wyden, Trump, Mylan


AstraZeneca's Lynparza meets main goal of late-stage cancer study

(Reuters) - British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for pancreatic cancer. The study showed Lynparza, which is currently being used as treatments for ovarian and breast cancer, was better at preventing the disease from becoming worse when compared to a placebo. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)
Tags: Science, Astrazeneca, Bengaluru, Reuters, Merck Co, Lynparza, AstraZeneca PLC, Pushkala Aripaka


AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer. The study showed that Lynparza was successful as a first-line maintenance treatment for adults with a form of genetically-mutated pancreatic cancer called germline BRCA -mutated metastatic adenocarcinoma of the pancreas. Lynparza, which is currently being used as a treatment for ovarian and breast c...
Tags: Science, Astrazeneca, Merck Co, Lynparza, AstraZeneca PLC


Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More

The growing epidemic of the fatty liver disease known as NASH, which has no FDA-approved treatment, has led to a frenzied race among drug companies. This week, one company, Intercept Pharmaceuticals, solidified its lead. But how much will being first to the finish line mean when all is said and done?Intercept (NASDAQ: ICPT) reported interim data from a Phase 3 study showing its drug, obeticholic acid (OCA), reduced liver scarring in NASH patients. The results should be enough to support an appr...
Tags: Deals, Startups, Drugs, Cancer, Trends, Investing, Merck, Leukemia, Acne, Inflammatory Bowel Disease, Xerox, Astrazeneca, Fda, National, Pfizer, Abbvie


4 shares with dividend growth potential? Barclays PLC, Tesco PLC, AstraZeneca plc and BP plc - Investomania

   Investomania The income investing potential of Barclays PLC (LON:BARC) (BARC.L), Tesco PLC (LON:TSCO) (TSCO.L), AstraZeneca plc (LON:AZN) (AZN.L) and BP plc ...
Tags: Shopping, Astrazeneca, Bp, Barclays PLC, Investomania, Barclays PLC Tesco PLC AstraZeneca, BARC BARC L Tesco PLC


Merck to further study Keytruda in prostate cancer after early success

(Reuters) - Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for prostate cancer after the drug showed anti-tumor activity in an early-stage trial. The interim findings of the trial testing Keytruda in combination with other cancer drugs such as Lynpraza, which it jointly develops and sells with AstraZeneca, and chemotherapy docetaxel showed anti-tumor activity, Merck said. "These promising data .. ...
Tags: Science, Merck, Astrazeneca, KEYTRUDA, REUTERS Merck Co Inc


New cancer drugs help upbeat AstraZeneca beat forecasts

AstraZeneca forecast a second straight year of sales growth on Thursday, driven by cancer medicines and other new drugs as the British drugmaker recovers from losing major patents.
Tags: Money, businessNews, Astrazeneca


AstraZeneca tops sales forecasts, stays calm on Brexit

British drugmaker AstraZeneca Plc beat expectations for product sales in the fourth quarter and forecast a second consecutive year of growth, driven by gains in emerging markets including China and demand for its new cancer medicines.
Tags: Money, China, businessNews, Astrazeneca, AstraZeneca PLC


Coastal startups don’t have a monopoly on raising big at early-stage

Jason Rowley Contributor Jason Rowley is a venture capital and technology reporter for Crunchbase News. More posts by this contributor Following a record year, Illinois startups kick off 2019 on a strong foot Global VC market sees highest-ever concentration of supergiant dollar volume in Q4 2018 Early-stage startups throughout much of the U.S. are able to raise larger sums today than any other point in at least a decade, and there...
Tags: Startups, TC, Column, Microsoft, Minneapolis, Atlanta, Chicago, Austin, Venture Capital, Astrazeneca, SEC, Ohio, North America, Illinois, Detroit, South


4 ‘surprising’ dividend shares? Tesco PLC, AstraZeneca plc, Aviva plc and Taylor Wimpey plc - Investomania

   Investomania Could these shares generate high income returns? Tesco PLC (LON:TSCO) (TSCO.L), AstraZeneca plc (LON:AZN) (AZN.L), Aviva plc (LON:AV) (AV.L) and ...
Tags: Shopping, Taylor Wimpey, Astrazeneca, Tesco PLC, Tesco PLC AstraZeneca plc Aviva plc


Lack of transparency in healthcare startups risks another Theranos implosion

Are more Theranos -style scandals looming for investors in healthcare startups? A team of researchers associated with the Meta Research Innovation Center at Stanford thinks so. They’ve  published a paper warning investors in life sciences startups that a systemic lack of transparency exists in their portfolio companies — creating the possibility for more multi-billion dollar implosions and scandals like the one that toppled Theranos and its charismatic founder, Elizabeth Holmes. Indeed, one of...
Tags: TC, Entrepreneurship, Stanford, Cancer, Articles, Tech, Companies, Diabetes, University, Healthcare, Food And Drug Administration, Astrazeneca, Fda, Cancer Treatment, Device, Abbvie


AstraZeneca Departures Continue as Medical Chief Bohen Exits

Sean Bohen, who’s also executive vice president for global medicines development, will part ways with Cambridge, England-based AstraZeneca after it completes the transition to the new structure unveiled last week, a spokesman said in emailed answers to questions. Chief Executive Officer Pascal Soriot announced the overhaul last week, bringing in a cancer expert, Jose Baselga, to reign over oncology research and development.
Tags: Science, Astrazeneca, Pascal Soriot, José Baselga, Cambridge England, Sean Bohen, AstraZeneca Departures Continue


Aptamer Group and AstraZeneca sign agreement to explore feasibility of developing drug delivery vehicles

Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney.
Tags: Health, Astrazeneca, Aptamer Group


Top Cancer Doctor, Forced Out Over Ties to Drug Makers, Joins Their Ranks

AstraZeneca has hired Dr. José Baselga, the former chief medical officer at Memorial Sloan Kettering, to lead its cancer research unit.
Tags: News, Cancer, Astrazeneca, Conflicts Of Interest, Jose, AstraZeneca PLC, Baselga, José Baselga, Memorial Sloan-Kettering Cancer Center, Memorial Sloan Kettering, Drugs (Pharmaceuticals


AstraZeneca appoints Baselga to head R&D for oncology

(Reuters) - AstraZeneca Plc has appointed José Baselga to head research and development for oncology as it looks to align the unit with its commercial operations to drive growth. Baselga resigned as Memorial Sloan Kettering Cancer Center's chief medical officer in September 2018 after a New York Times and Pro Publica investigation revealed that he had not disclosed millions of dollars in payments from healthcare companies in many of his research articles. ...
Tags: Science, New York Times, Astrazeneca, Baselga, Memorial Sloan Kettering Cancer Center, José Baselga, Reuters AstraZeneca Plc


AstraZeneca picks Baselga to lead oncology R&D in growth plan

AstraZeneca said on Monday it had hired José Baselga to head research and development in oncology, an area where the British drugs firm is seeking to grow its business.
Tags: Money, businessNews, Astrazeneca, José Baselga


Ribon Raises $65M to Pursue PARP-Blocking Pills for Cancer

A new class of ovarian and breast cancer drugs that thwart a DNA repair mechanism ushered in a novel approach to treating cancer. The first PARP inhibitor was approved in 2014. That drug, and others that followed, block a PARP enzyme that plays a key role in this repair process. But it turns out there’s more than one type of PARP—17, to be exact. Ribon Therapeutics aims to target other PARPs with small molecule drugs, and the Boston-area startup has raised $65 million in financing to bring its ...
Tags: Deals, Startups, Boston, Cancer, Funding, Trends, Venture Capital, Astrazeneca, Biotech, Series B, Life Sciences, Oncology, Celgene, Olaparib, Osage University Partners, National blog main


4 ‘bargain’ FTSE 100 shares? Tesco PLC, AstraZeneca plc, Aviva plc and Next plc - Investomania

   Investomania Do these stocks offer good value for money? Tesco PLC (LON:TSCO) (TSCO.L), AstraZeneca plc (LON:AZN) (AZN.L), Aviva plc (LON:AV) (AV.L) and Next plc ...
Tags: Shopping, Astrazeneca, Tesco PLC, Tesco PLC AstraZeneca plc Aviva plc


AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting

AstraZeneca's (AZN) Lynparza receives FDA approval for first-line maintenance treatment of advanced ovarian cancer.
Tags: Science, Astrazeneca, Fda, AZN Lynparza


Aristea Therapeutics Raises $15M to Develop Anti-Inflammatory Drugs

New biopharma company Aristea Therapeutics has raised $15 million from Novo Holdings, the Danish investment company, and secured global rights to an investigational AstraZeneca drug that’s ready for Phase 2 study.The San Diego, CA, company made its public debut this week after starting up quietly earlier this year.Aristea expects its lead program, RIST4721, the drug candidate it licensed from AstraZeneca, will enter a Phase 2 clinical trial early next year. The company also plans to develop dru...
Tags: Trends, Investment, Vc, Gout, Venture Capital, San Diego, Astrazeneca, Biotech, Novo Nordisk, Life Sciences, Grünenthal, Clinical Trials, Ardea Biosciences, National blog main, Boston blog main, San Diego blog main


RiverVest Venture Closes $184M Fund for Backing Healthcare Ventures

RiverVest Venture Partners, a St. Louis, MO-based venture capital firm with additional offices in San Diego, CA, and Cleveland, OH, has raised $184.4 million for its fourth fund dedicated to investing in healthcare companies.Since its launch, RiverVest has invested in 47 companies working to develop new drugs and medical devices. Nearly half of the businesses in its portfolio have either been acquired or gone public, according to RiverVest.Among the notable exits was San Diego’s Lumena Pharmace...
Tags: Deals, Money, Trends, Vc, Venture Capital, San Diego, Astrazeneca, Biotech, Medical Device, Life Sciences, Abbott Laboratories, San Diego CA, St Louis MO, Cleveland OH, Cambridge Associates, ZS Pharma


China first to approve AstraZeneca, FibroGen anaemia drug

China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.
Tags: Money, China, businessNews, United States, Astrazeneca, FibroGen


CETSA HT in early drug discovery through screening against B-Raf and PARP1

A new study published ahead-of-print by SLAS Discovery describes an evaluation of microplate-based high-throughput cellular thermal shift assay (CETSA HT) performed at AstraZeneca to assess its suitability and reliability for application to early drug discovery campaigns.
Tags: Astrazeneca, Raf


Cancer Research UK and AstraZeneca open new Functional Genomics Centre

Cancer Research UK and AstraZeneca have announced today (Monday) that they are opening a new center in the UK, dedicated to realizing the full potential of functional genomics in the discovery and development of new drugs for patients with cancer.
Tags: Health, UK, Astrazeneca, Cancer Research UK


Bio Roundup: ASH Wrap, CRISPR Baby Fallout, Moderna’s Record IPO

The biggest yearly meeting for blood disease research has come and gone, and yet the stories to come out of the American Society of Hematology’s gathering in San Diego represent just a fraction of what happened in biopharma this week.Even if ASH wasn’t on your radar, the CRISPR baby saga—the apparent birth of gene edited twin girls in China that shocked the life sciences world a few weeks ago—rolled on. One massive buyout was signed, and another even bigger one inched closer to being finalized....
Tags: Deals, Startups, China, Ipo, Trends, IPOs, People, Vc, Adhd, San Diego, Astrazeneca, Fda, National, GlaxoSmithKline, Novartis, Ash